AMERICAN BIOGENETIC SCIENCES, INC. RESPONDS TO INQUIRIES

Copiague, New York, November 28, 2001 – American Biogenetic Sciences, Inc. (ABS) (NASDAQ:MABA) issued a press release on Monday morning, November 26. The Nasdaq Stock Market contacted the company and asked the company to provide certain additional factual information with respect to the matters described in the press release. Pending receipt of that information, at 10:21 a.m. on Monday morning, The Nasdaq Stock Market halted trading in the company’s stock.

The company is actively working to provide The Nasdaq Stock Market with the requested information and resolve any issues as expeditiously as possible, but is unable at this time to predict exactly when these issues may be resolved and trading resumed.

American Biogenetic Sciences, Inc., is based in Copiague, NY, and researches and develops diagnostic tests for cardiopulmonary conditions and infectious diseases, as well as for new treatments for neurological disorders, including epilepsy, migraine, mania, and Alzheimer’s disease. As an innovative developer of biogenetic technologies and compounds, ABS to date has been issued over 75 patents, both US and foreign, and there are over 100 patents pending.

Statements in this release that are not strictly historical are “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 and should be considered as subject to various risks and uncertainties that could cause actual results to differ materially from those anticipated. For further details and a discussion of these risks and uncertainties, see ABS’ Securities and Exchange Commission filings including its annual report or 10-K form.

For more information, please contact:

For a complete analysis of the ABS’ pipeline go to: /research.html.